Long-term safety and efficacy data show that a CAR T-cell therapy produces high response rates in highly pretreated adult patients with relapsed or refractory DLBCL. READ MORE

News

Improvements in life expectancy and quality-adjusted life years as a result of chimeric antigen receptor T-cell therapy is dependent upon immediate access to treatment.

READ MORE

A JAMA Oncology research letter sheds light on the average additional costs associated with CAR-T therapy, which can be from $30,000 to $36,000 per patient.

READ MORE

Medicare will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000.

READ MORE

Younger patients who received certain chemotherapies for solid tumors or leukemia may not have T-cells capable of becoming effective CAR T-cells.

READ MORE

Features

Authors review the foundational research in CAR-T therapy, including pricing estimates, in order to determine how best to integrate this new branch of immuno-oncology into clinical pathways for patients with B-cell malignancies.

READ MORE

Author Insights

Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?

READ MORE

Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.

READ MORE

While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.

READ MORE

Interactive Features

What is the average cost per patient for additional therapy or adverse events after CAR-T therapy administration?

READ MORE

A recent study found that patients with non-Hodgkin lymphoma who received CAR-T therapy benefited, with an overall response rate of what percentage after a median of 15.4 months?

READ MORE

Interviews

Houston Holmes, MD, MBA, FACP, Texas Oncology, discusses the barriers to accessing CAR-T therapy for patients in the community setting and reveals what to expect with the next wave of CAR-T products.

READ MORE

B-Cell Malignancies

Long-term safety and efficacy data show that a CAR T-cell therapy produces high response rates in highly pretreated adult patients with relapsed or refractory DLBCL.

READ MORE

In a new study, researchers identified factors associated with high economic burden for patients with treated diffuse large B-cell lymphoma and follicular lymphoma.

READ MORE

A recent study sought to determine the factors associated with durable remission after a complete response to CD19-targeting chimeric antigen receptor T-cell therapy in adult patients with B-cell acute lymphoblastic leukemia.

READ MORE

A recent study demonstrated the real-world effectiveness and tolerability of a targeted agent for the treatment of relapsed or refractory mantle cell lymphoma.

READ MORE

Resources

The National Comprehensive Cancer Network released updated guidelines for a variety of B-cell lymphomas, including follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma.

READ MORE